acitretin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| retinol derivatives | 78 | 55079-83-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 35 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.83 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
| BA (Bioavailability) | 59 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 28, 1996 | FDA | STIEFEL LABS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pregnancy | 174.33 | 43.17 | 41 | 444 | 7908 | 2349692 |
| Exposure during pregnancy | 148.44 | 43.17 | 46 | 439 | 25173 | 2332427 |
| Psoriasis | 138.86 | 43.17 | 40 | 445 | 16968 | 2340632 |
| Drug exposure before pregnancy | 90.32 | 43.17 | 14 | 471 | 277 | 2357323 |
| Abortion induced | 87.00 | 43.17 | 20 | 465 | 3416 | 2354184 |
| Erythema | 76.25 | 43.17 | 28 | 457 | 25131 | 2332469 |
| Alopecia | 72.28 | 43.17 | 26 | 459 | 21975 | 2335625 |
| Drug ineffective | 61.56 | 43.17 | 37 | 448 | 101587 | 2256013 |
| Skin exfoliation | 57.69 | 43.17 | 16 | 469 | 5774 | 2351826 |
| Maternal exposure before pregnancy | 56.38 | 43.17 | 11 | 474 | 849 | 2356751 |
| Decreased appetite | 48.37 | 43.17 | 21 | 464 | 28870 | 2328730 |
| Type IIb hyperlipidaemia | 44.44 | 43.17 | 5 | 480 | 4 | 2357596 |
| Pustular psoriasis | 44.06 | 43.17 | 9 | 476 | 875 | 2356725 |
| Pregnancy of partner | 43.35 | 43.17 | 6 | 479 | 51 | 2357549 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vein rupture | 300.91 | 60.12 | 37 | 512 | 41 | 1746191 |
| Psoriasis | 300.86 | 60.12 | 77 | 472 | 11548 | 1734684 |
| Drug ineffective | 283.74 | 60.12 | 109 | 440 | 63692 | 1682540 |
| Injection site haemorrhage | 175.02 | 60.12 | 38 | 511 | 2699 | 1743533 |
| Myalgia | 153.78 | 60.12 | 49 | 500 | 15609 | 1730623 |
| Injection site swelling | 152.02 | 60.12 | 35 | 514 | 3236 | 1742996 |
| Pain in extremity | 149.83 | 60.12 | 50 | 499 | 18422 | 1727810 |
| Muscular weakness | 142.71 | 60.12 | 42 | 507 | 10207 | 1736025 |
| Venous injury | 135.57 | 60.12 | 18 | 531 | 50 | 1746182 |
| Insomnia | 131.55 | 60.12 | 44 | 505 | 16232 | 1730000 |
| Headache | 129.85 | 60.12 | 53 | 496 | 34323 | 1711909 |
| Injection site papule | 96.47 | 60.12 | 14 | 535 | 86 | 1746146 |
| Skin plaque | 83.56 | 60.12 | 17 | 532 | 863 | 1745369 |
| Nausea | 82.84 | 60.12 | 44 | 505 | 51152 | 1695080 |
| Granuloma annulare | 80.74 | 60.12 | 11 | 538 | 39 | 1746193 |
| Erythema | 71.04 | 60.12 | 27 | 522 | 14161 | 1732071 |
| Induration | 64.01 | 60.12 | 11 | 538 | 218 | 1746014 |
| Condition aggravated | 60.61 | 60.12 | 27 | 522 | 21123 | 1725109 |
| Skin exfoliation | 60.19 | 60.12 | 18 | 531 | 4517 | 1741715 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D05BB02 | DERMATOLOGICALS ANTIPSORIATICS ANTIPSORIATICS FOR SYSTEMIC USE Retinoids for treatment of psoriasis |
| FDA EPC | N0000175607 | Retinoid |
| FDA Chemical/Ingredient | N0000007700 | Retinoids |
| CHEBI has role | CHEBI:50176 | keratolytic drug |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D007641 | Keratolytic Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Severe Recalcitrant Psoriasis | indication | ||
| Lichen planus | off-label use | 4776004 | DOID:9201 |
| Keratosis follicularis | off-label use | 48611009 | DOID:2734 |
| Lamellar ichthyosis | off-label use | 205550003 | |
| Ichthyosiform erythroderma | off-label use | 268282005 | |
| Primary cutaneous T-cell lymphoma | off-label use | 400122007 | |
| Alcoholism | contraindication | 7200002 | |
| Hypercholesterolemia | contraindication | 13644009 | |
| Depressive disorder | contraindication | 35489007 | |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Night blindness | contraindication | 65194006 | DOID:8499 |
| Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Premature epiphyseal closure | contraindication | 89493005 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Hypoalphalipoproteinemia | contraindication | 190785000 | |
| Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
| Hypertrophy of bone | contraindication | 203514008 | DOID:205 |
| Drug-induced hepatitis | contraindication | 235876009 | |
| Pregnancy, function | contraindication | 289908002 | |
| Hypertriglyceridemia | contraindication | 302870006 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Visual impairment | contraindication | 397540003 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Psychiatric Disturbance | contraindication |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.17 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Retinoic acid receptor alpha | Nuclear hormone receptor | AGONIST | WOMBAT-PK | CHEMBL | |||||
| Retinoic acid receptor gamma | Nuclear hormone receptor | AGONIST | CHEMBL | CHEMBL | |||||
| Bile salt export pump | Transporter | IC50 | 4.74 | CHEMBL | |||||
| Bile salt export pump | Unclassified | IC50 | 4.71 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021061 | VUID |
| N0000148524 | NUI |
| C0050559 | UMLSCUI |
| D02754 | KEGG_DRUG |
| 108914001 | SNOMEDCT_US |
| 4021061 | VANDF |
| 16818 | RXNORM |
| 386938006 | SNOMEDCT_US |
| 4128 | MMSL |
| d03836 | MMSL |
| 117161 | MMSL |
| 004121 | NDDF |
| BK59Y5A02O | UNII |
| 69427-46-9 | SECONDARY_CAS_RN |
| CHEMBL1131 | ChEMBL_ID |
| DB00459 | DRUGBANK_ID |
| 5530 | INN_ID |
| CHEBI:50173 | CHEBI |
| 7598 | IUPHAR_LIGAND_ID |
| 5284513 | PUBCHEM_CID |
| D017255 | MESH_DESCRIPTOR_UI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1135 | CAPSULE | 10 mg | ORAL | ANDA | 16 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1136 | CAPSULE | 25 mg | ORAL | ANDA | 16 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1138 | CAPSULE | 17.50 mg | ORAL | ANDA | 16 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1667 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1668 | CAPSULE | 17.50 mg | ORAL | ANDA | 17 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1669 | CAPSULE | 25 mg | ORAL | ANDA | 17 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1698 | CAPSULE | 22.50 mg | ORAL | ANDA | 17 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1750 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1751 | CAPSULE | 17.50 mg | ORAL | ANDA | 17 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1752 | CAPSULE | 22.50 mg | ORAL | ANDA | 17 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1753 | CAPSULE | 25 mg | ORAL | ANDA | 17 sections |
| SORIATANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0145-0090 | CAPSULE | 10 mg | ORAL | NDA | 16 sections |
| SORIATANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0145-0091 | CAPSULE | 25 mg | ORAL | NDA | 16 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7020 | CAPSULE | 10 mg | ORAL | ANDA | 16 sections |
| Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7023 | CAPSULE | 25 mg | ORAL | ANDA | 16 sections |
| ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-086 | CAPSULE | 10 mg | ORAL | ANDA | 14 sections |
| ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-087 | CAPSULE | 17.50 mg | ORAL | ANDA | 14 sections |
| ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-088 | CAPSULE | 25 mg | ORAL | ANDA | 14 sections |
| ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-080 | CAPSULE | 10 mg | ORAL | ANDA | 14 sections |
| ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-081 | CAPSULE | 17.50 mg | ORAL | ANDA | 14 sections |
| ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-083 | CAPSULE | 25 mg | ORAL | ANDA | 14 sections |
| ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-894 | CAPSULE | 10 mg | ORAL | NDA authorized generic | 15 sections |
| ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-896 | CAPSULE | 25 mg | ORAL | NDA authorized generic | 15 sections |